Questcor Pharmaceuticals (FRA:QPH) 6-1 Month Momentum % : N/A% (As of Jun. 30, 2025)

View and export this data going back to . Start your Free Trial

What is Questcor Pharmaceuticals 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-06-30), Questcor Pharmaceuticals's 6-1 Month Momentum % is N/A%.

The industry rank for Questcor Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:

FRA:QPH's 6-1 Month Momentum % is not ranked ^*
in the Biotechnology industry.
Industry Median: -11.64
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Competitive Comparison of Questcor Pharmaceuticals's 6-1 Month Momentum %

For the Biotechnology subindustry, Questcor Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Questcor Pharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Questcor Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Questcor Pharmaceuticals's 6-1 Month Momentum % falls into.

Save Embed

;

Save Embed

;

Questcor Pharmaceuticals (FRA:QPH) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Questcor Pharmaceuticals (FRA:QPH) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Questcor Pharmaceuticals 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Questcor Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Questcor Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Questcor Pharmaceuticals Inc (FRA:QPH) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.questcor.com

Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.

Questcor Pharmaceuticals Headlines

No Headlines